Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American breast cancer intergroup trial E 2197

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4092-4099

  Goldstein, Lori J ^a   O'Neill, Anne ^a   Sparano, Joseph A ^a   Perez, Edith A ^a   Shulman, Lawrence N ^a   Martino, Silvana ^a   Davidson, Nancy E ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG FATALITY; FEMALE; FEVER; FOLLOW UP; HAZARD RATIO; HEART ARREST; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INFECTION; ISCHEMIA; LEUKOPENIA; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; TAXOIDS;

EID: 51749093141     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.7841     Document Type: Article

References (36)

1. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
2. Bishop JF, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17:2355-2364, 1999
3. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999
4. Ghersi D, Wilcken N, Simes J, et al: Taxane containing regimens for metastatic breast cancer. Br J Cancer 93:293-301, 2005
5. Crown J, Dieras V, Kaufmann M, et al: Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol 3:719-727, 2002
6. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 21:588-592, 2003
7. Sparano JA, Hu P, Rao RM, et al: Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 17:3828-3834, 1999
8. Dombernowsky P, Gehl J, Boesgaard M, et al: Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 22:13-17, 1995
9. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
10. Sparano JA, O'Neill A, Schaefer PL, et al: Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group study E1196. J Clin Oncol 18:2369-2377, 2000
11. Sparano JA, Hu P, Raor RM, et al: Phase II trial of doxorubicin plus paclitaxel plus G-CSF in metastatic breast cancer: An Eastern Cooperative Oncology Group study (E4195). Breast Cancer Res Treat 46, 1997
12. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
13. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
14. Crown JP, Francis P, Di Leo A: Docetaxel given either concurrently or sequentially to anthracycline-based adjuvant therapy for patients with node-positive breast cancer: comparison with non-taxane combination chemotherapy: First results of the BIG 2-98 trial at 5 years median follow-up. J Clin Oncol 24:7s, 2006 (suppl; abstract LBA519)
15. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
16. Roche H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial. J Clin Oncol 24:5664-5671, 2006
17. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines: American Society of Clinical Oncology. J Clin Oncol 14:1957-1960, 1996
18. Mansour EG, Gray RJ, Shatila A, et al: Efficacy of adjuvant chemotherapy in high risk node negative breast cancer. N Engl J Med 320:485-490, 1989
19. Davidson NE, O'Neill AM, Vukov AM, et al: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol 23:5973-5982, 2005
20. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:5490556, 1979
21. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819-825, 1984
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
24. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 187-220, 1972
25. Wald A: Tests of statistical hypotheses concerning several parameters when the number of parameters is large. Trans Am Math Soc 54:426-482, 1943
26. Misset JL, Dieras V, Gruia G, et al: Dose-finding study of docetaxel and doxorubicin in firstline treatment of patients with metastatic breast cancer. Ann Oncol 10:553-560, 1999
27. Nabholtz JM, Falkson C, Campos D, et al: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975, 2003
28. Cresta S, Grasselli G, Mansutti M, et al: A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 15:433-439, 2004
29. Martin M, Lluch A, Segui MA: Toxicity and health-related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: Impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. J Clin Oncol 23:29s, 2005 (suppl; abstr 604).
30. Ferguson T, Wilcken N, Vagg R, et al: Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev CD004421, 2007
31. De Laurentiis M, Cancello G, D'Agostino D, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 26:44-53, 2008
32. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
33. Jones SE, Holmes FA, O'Shaughnessy JA, et al: Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735:Docetaxel/ cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/ cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 106:S5, 2007 (abstr 12)
34. Harvey V, Mouridsen H, Semiglazov V, et al: Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963-4970, 2006
35. Badve SS, Baehhner FM, Gray RP, et al: Estrogen and progesterone receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
36. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006